CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 72.3% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2026 Jan 14, 11:33

A Look At BioNTech (BNTX) Valuation After Expanded Oncology Pipeline Update

BioNTech SE
Webhose 2026 Jan 14, 09:04

BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan

BioNTech SE
Webhose 2026 Jan 09, 13:51

Big Pharma turf war erupts: Bayer sues vaccine makers over alleged stolen mRNA technology - NaturalNews.com

BioNTech SE
Webhose 2026 Jan 09, 02:30

Monsanto Sues COVID-19 Vaccine Manufacturers, Alleging Copyright Infringement | ZeroHedge

BioNTech SE
Webhose 2026 Jan 09, 00:00

Pancreatic cancer: advances in immunology, translational analyses and therapeutic paradigms

BioNTech SE
Webhose 2026 Jan 08, 03:29

BioNTech (BNTX) Is Up 5.1% After 90%-Effective COVID Data Raises New Franchise Questions

BioNTech SE
Webhose 2026 Jan 08, 00:43

Bayer sues Pfizer, Moderna, J&J and BioNTech over alleged Covid vaccine patent breach | Malay Mail

BioNTech SE
Webhose 2026 Jan 07, 13:03

Bayer sues Covid-jab makers, alleging patent violation

BioNTech SE
Webhose 2026 Jan 07, 10:24

Bayer's Monsanto Files Lawsuit Against Pfizer, BioNTech, and Moderna Over mRNA Patent Infringement, ETPharma

BioNTech SE
Webhose 2026 Jan 07, 00:34

BioNTech (NasdaqGS:BNTX) Valuation Check After Positive COVID 19 Vaccine Efficacy Data

BioNTech SE
Webhose 2026 Jan 03, 00:00

The Future of mRNA Is Being Built in APAC

BioNTech SE
Webhose 2026 Jan 01, 06:34

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Recommendation of "Moderate Buy" from Analysts

BioNTech SE
Webhose 2025 Dec 28, 11:39

BioNTech SE Sponsored ADR $BNTX Shares Sold by TB Alternative Assets Ltd.

BioNTech SE
Webhose 2025 Dec 28, 05:40

Swedbank AB Has $4.92 Million Stake in BioNTech SE Sponsored ADR $BNTX - Stock Observer

BioNTech SE
Webhose 2025 Dec 26, 10:46

Vontobel Holding Ltd. Purchases 10,924 Shares of BioNTech SE Sponsored ADR $BNTX - Markets Daily

BioNTech SE
Webhose 2025 Dec 23, 05:53

BioNTech SE (BNTX) Closes the Acquisition of CureVac N.V.

BioNTech SE
Webhose 2025 Dec 21, 16:33

10 Stocks That Will Go To The Moon in 2026

BioNTech SE
Webhose 2025 Dec 19, 05:00

Other news to note for Dec. 19, 2025 | BioWorld

BioNTech SE

BioNTech news

Latest news

Show more

Info

Spread

1.0853

Spread (%)

0.9987 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Thursday

14:31 - 20:59

Monday

14:31-20:59

Tuesday

14:31-20:59

Wednesday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

26897266688

Shares Outstanding

250930737

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-2.79

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Trustpilot